ProKidney Corp. develops rilparencel, also described as REACT or Renal Autologous Cell Therapy, as an autologous cell therapy candidate for patients with advanced chronic kidney disease and diabetes. News about PROK centers on clinical data from REGEN-007, Phase 3 PROACT 1/REGEN-006 development, regulatory interactions with the FDA on the use of eGFR slope in an accelerated approval pathway, and scientific presentations in nephrology forums.
Company updates also cover quarterly and annual financial results, cash runway commentary, investor conference participation, and leadership additions tied to commercial planning for rilparencel.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.